BioFluidica, a Chapel Hill company developing a product using liquid biopsies for cancer detection. has completed a $2 million Series A funding round.

The company, founded in 2007 by Steven Soper, Ph.D., professor of chemistry and biomedical engineering at the University of North Carolina at Chapel Hill, is developing instruments to isolate and analyze tumor cells and biomarkers circulating in the bloodstream.

The North Carolina Biotechnology Center awarded BioFluidica a $250,000 Small Business Research Loan late last year. Now the company has about eight employees in Chapel Hill, and has posted job openings for more. It also has a facility in San Diego.

The venture investment was made public byBioFluidics CEO Rolf Muller in a filing with the Securities and Exchange Commission.

(C) N.C. Biotechnology Center